HCPLive Network

IDSA 2011: Dr. Christian Loucq on Successful Initial Results of a Malaria Vaccine Trial [Podcast]

BOSTON, MA—In this interview at the annual conference of the Infectious Diseases Society of America, Christian Loucq, MD, director of the PATH Malaria Vaccine Initiative, discusses promising initial results of a Phase III trial of the experimental malaria vaccine RTS,S.
Further Reading
Clinicians may one day be able to offer more effective, personalized treatment to patients diagnosed with lupus thanks to a potential breakthrough in DNA sequencing.
Emergency physicians may see an increase in heroin overdoses that are actually tied to acetyl fentanyl, a legal opiate with effects mirroring heroin.
The panel continues its discussion by looking at several therapies used to treat patients with lipodystrophy.
Alessio Fasano, MD, came to the US from Italy looking to expand his horizons beyond celiac disease. Instead, he became a leader in the treatment, research, and education of celiac disease and other gluten-related disorders.
Researchers have made several impressive advances in gastrointestinal medicine in recent years, including the use of fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infection. Following the success of that approach, researchers have been evaluating FMT for the treatment of other conditions, with one team recently conducting the first randomized controlled trial of FMT to treat inflammatory bowel disease (IBD).
One-pill regiment includes abacavir, dolutegravir and lamivudine.
Researchers have manufactured a peptide aimed to block modified proteins associated with Alzheimer’s disease, Parkinson’s disease, heart disease, Type 2 diabetes, Lou Gehrig’s disease, and other conditions.
More Reading
Clinicians may one day be able to offer more effective, personalized treatment to patients diagnosed with lupus thanks to a potential breakthrough in DNA sequencing.